Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Teva
Argus Health
Accenture
Colorcon
Cantor Fitzgerald
Johnson and Johnson
Deloitte
US Department of Justice

Generated: February 23, 2019

DrugPatentWatch Database Preview

MYOBLOC Drug Profile

« Back to Dashboard

Summary for Tradename: MYOBLOC
Pharmacology for MYOBLOC

US Patents for MYOBLOC

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan, Inc. (Irvine, CA) ➤ Sign Up RX search
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan, Inc. (Irvine, CA) ➤ Sign Up RX search
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan, Inc. (Irvine, CA) ➤ Sign Up RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan Sales, Inc. (Irvine, CA) ➤ Sign Up RX search
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan Sales, Inc. (Irvine, CA) ➤ Sign Up RX search
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan Sales, Inc. (Irvine, CA) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for MYOBLOC

Supplementary Protection Certificates for MYOBLOC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
92780 Luxembourg ➤ Sign Up PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
PA2015031 Lithuania ➤ Sign Up PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
300753 Netherlands ➤ Sign Up PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
10C0007 France ➤ Sign Up PRODUCT NAME: TOXINE BOTULIQUE DE TYPE B; REGISTRATION NO/DATE: EU/1/00/166/001 20010122
122015000061 Germany ➤ Sign Up PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
CA 2016 00031 Denmark ➤ Sign Up PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cipla
Baxter
Accenture
Teva
Johnson and Johnson
AstraZeneca
Fuji
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.